Zhongyuan Union Cell & Gene Engineering Corp Ltd
600645
Company Profile
Business description
Zhongyuan Union Cell & Gene Engineering Corp Ltd is engaged in stem cell technology research, as well as detection and storage sources of stem cells in China. The company insists on the core strategy upon dual-core development of 'cell + gene' with the major businesses covering various cell storage businesses of newborns and adults; the preparation and storage of cord blood hematopoietic stem cells, umbilical cord mesenchymal stem cells, placental pluripotent stem cells, adipose-derived stem cells and immune cells; genetic testing services relating to children's genes.
Contact
45 East of Tianjin Airport Economic Zone nine
Tianjin300304
CHNT: +86 2258775766
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
1,935
Stocks News & Analysis
stocks
AMD: We’re pleased with Anthropic Partnership ahead of advancing AI event
We’re encouraged that AMD will count Anthropic as a third leading AI customer, in addition to OpenAI and Meta.
stocks
The most popular ASX trades in FY26
A closer look at the stocks and ETFs that captured Aussie investors’ attention in FY26.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,055.60 | 3.90 | -0.04% |
| CAC 40 | 8,437.89 | 74.75 | 0.89% |
| DAX 40 | 25,155.41 | 144.06 | 0.58% |
| Dow JONES (US) | 52,218.58 | 6.06 | -0.01% |
| FTSE 100 | 10,716.97 | 131.06 | 1.24% |
| HKSE | 25,201.90 | 309.24 | 1.24% |
| NASDAQ | 25,690.90 | 146.30 | -0.57% |
| Nikkei 225 | 66,424.44 | 308.84 | 0.47% |
| NZX 50 Index | 13,726.25 | 36.93 | -0.27% |
| S&P 500 | 7,498.96 | 10.24 | -0.14% |
| S&P/ASX 200 | 8,874.40 | 3.20 | -0.04% |
| SSE Composite Index | 3,858.28 | 8.76 | -0.23% |